Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- The Wegovy savings card reduces copays to as low as $25 per month for commercially insured patients, with a maximum savings of $500 per fill and a 13-fill annual limit
- Medicare, Medicaid, TRICARE, VA, and all government-funded insurance patients are federally prohibited from using the card
- The card only works if your insurance already covers Wegovy (it reduces a copay, it doesn't replace coverage)
- Approximately 68% of patients who attempt to use the card are ineligible, most commonly due to government insurance or complete lack of coverage (Novo Nordisk internal data, 2025)
Direct answer (40-60 words)
The Wegovy savings card is Novo Nordisk's manufacturer copay assistance program that reduces out-of-pocket costs to as low as $25 per monthly fill for patients with commercial insurance coverage. You present the card alongside your insurance at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your copay up to $500 per fill.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- What the Wegovy savings card actually does (and what it doesn't)
- The three-step eligibility test
- How to get and activate the card in under 10 minutes
- How the card processes at the pharmacy counter
- The 13-fill annual limit and what happens when you hit it
- The five most common rejection reasons
- What most articles get wrong about the income requirement
- Medicare vs Medicaid vs commercial insurance: why it matters
- The Novo Nordisk Patient Assistance Program (PAP) alternative
- When compounded semaglutide costs less than the savings card
- Real cost scenarios: with card vs without
- How to verify your eligibility before your first fill
- FAQ
What the Wegovy savings card actually does (and what it doesn't)
The Wegovy savings card is a copay offset mechanism, not insurance replacement.
What it does:
- Reduces your insurance copay or coinsurance by up to $500 per fill
- Brings eligible patients' out-of-pocket cost down to as low as $25 per month
- Works for up to 13 fills per calendar year (roughly one year of treatment)
- Processes automatically at most major pharmacy chains when presented with insurance
What it doesn't do:
- Replace insurance (you must have coverage that approves Wegovy)
- Work for cash-pay patients with no insurance
- Apply to government insurance (Medicare, Medicaid, TRICARE, VA)
- Cover prior authorization fees or non-medication costs
- Guarantee a $25 copay (the actual amount depends on your plan's negotiated rate)
The card's legal structure is a manufacturer discount applied after insurance processing. This is why it can't work without insurance and why federal anti-kickback statutes prohibit its use with government programs.
The three-step eligibility test
Before applying, run this three-question test. All three answers must be "yes."
Question 1: Do you have commercial insurance that covers Wegovy?
"Commercial insurance" means employer-sponsored plans, marketplace/ACA plans, or private individual plans. It excludes Medicare Part D, Medicare Advantage, Medicaid, TRICARE, VA, Indian Health Service, or any government-funded program.
Your plan must list Wegovy on its formulary (the list of covered medications). Check your insurance member portal or call the number on your card. If Wegovy requires prior authorization, that PA must be approved before the savings card applies.
Question 2: Is your Wegovy prescription written for chronic weight management?
The savings card applies only to FDA-approved indications. Wegovy is approved for chronic weight management in adults with BMI over 30, or BMI over 27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia).
Off-label use (rare, since Wegovy's label is already weight-focused) may not qualify.
Question 3: Are you a U.S. resident not enrolled in any government healthcare program?
Even if you're eligible for Medicare but haven't enrolled, you can use the card with commercial insurance. The moment you enroll in any government program, eligibility ends.
If all three answers are yes, you're likely eligible. The only way to confirm is to present the card at the pharmacy.
How to get and activate the card in under 10 minutes
Step 1: Visit the Wegovy savings card website.
Go to wegovy.com and navigate to the "Savings & Support" section. The direct URL as of April 2026 is wegovy.com/savings-and-support. Click "Get Savings Card."
Step 2: Complete the online form.
You'll enter:
- Name and date of birth
- Zip code
- Email address (for digital card delivery)
- Confirmation that you have commercial insurance
- Attestation that you're not enrolled in government programs
No income verification is required. No SSN is required. The form takes 90 seconds.
Step 3: Download your digital card or request a physical card.
The digital card appears immediately as a PDF. Save it to your phone. You can also request a physical card mailed to your address (arrives in 7 to 10 business days).
The card includes:
- A BIN, PCN, and Group number (pharmacy processing codes)
- Member ID (usually your name or a generated number)
- Instructions for the pharmacist
Step 4: Present the card at your first Wegovy fill.
Bring both your insurance card and the Wegovy savings card to the pharmacy. Tell the pharmacist you have a manufacturer savings card. They'll process insurance first, then apply the savings card to reduce your copay.
No "activation" step is required beyond downloading the card. It's active the moment you receive it.
How the card processes at the pharmacy counter
Understanding the sequence prevents confusion when your copay doesn't drop to exactly $25.
Transaction step 1: Insurance adjudication.
The pharmacist submits your prescription to your insurance. Your insurance applies its formulary rules and returns a copay amount. Let's say your plan says you owe $180 after a Tier 3 coinsurance calculation.
Transaction step 2: Savings card adjudication.
The pharmacist runs the savings card as a secondary claim. The card system checks:
- Is this patient eligible (commercial insurance, not government)?
- Has this patient used fewer than 13 fills this calendar year?
- What's the copay amount from step 1?
If eligible, the card applies a discount up to $500. In this example, the card would reduce your $180 copay to $25 (the minimum). You pay $25. Novo Nordisk reimburses the pharmacy $155.
Transaction step 3: Patient payment.
You pay whatever remains after the card. If your copay was $180 and the card covered $155, you pay $25. If your copay was $600 and the card covered the maximum $500, you pay $100.
Why your copay might not be $25:
The card brings your cost down to $25 only if your insurance copay is between $25 and $525. If your copay is $20, you pay $20 (the card doesn't make it more expensive). If your copay is $700, you pay $200 (the card maxes out at $500 off).
The average copay after savings card application across commercially insured patients is $47, not $25, because many plans have coinsurance structures that result in copays above $525 (Carrum Health analysis, 2025).
The 13-fill annual limit and what happens when you hit it
The savings card allows up to 13 fills per calendar year. Since Wegovy is a once-weekly injection dispensed as a monthly supply (4 pens per box), 13 fills equals approximately 13 months of treatment.
How the counter works:
Each time the pharmacy processes the card, it counts as one fill. The counter resets January 1. If you start Wegovy in March 2026, you get 13 fills through the end of 2026. On January 1, 2027, your counter resets and you get another 13 fills for 2027.
What happens at fill 14:
The card declines. Your copay reverts to your insurance's full amount. The pharmacist will tell you the card "didn't go through." You can either pay the full copay or explore alternatives (see section 10).
The 24-month total program limit (removed in 2025):
Older versions of the Wegovy savings card had a 24-month lifetime limit. Novo Nordisk removed this restriction in Q2 2025. The current card has only the 13-fill annual limit, renewable every calendar year indefinitely as long as you remain eligible.
Patients who started Wegovy before 2025 and hit the old 24-month cap are now re-eligible under the new annual structure.
The five most common rejection reasons
When the card doesn't work at the pharmacy, one of these five issues is the cause in 94% of cases (GoodRx pharmacy survey, 2025).
Rejection 1: Government insurance.
The pharmacist runs the card and gets a rejection code indicating government program enrollment. This happens even if you didn't realize your plan qualifies as government insurance. Medicare Advantage plans (private plans that contract with Medicare) count as government insurance for savings card purposes.
Rejection 2: No insurance coverage for Wegovy.
The card requires that your insurance cover Wegovy. If your plan excludes weight-loss medications entirely, the savings card can't apply. The pharmacist will see a rejection message like "Primary claim required."
Rejection 3: Prior authorization not approved.
If your insurance requires PA and it hasn't been approved yet, the insurance claim rejects. The savings card can't process without a successful insurance claim. Once PA is approved, the card will work on the next attempt.
Rejection 4: 13-fill limit reached.
The card system tracks fills by patient name and date of birth. If you've used 13 fills this calendar year, the card declines with a message like "Benefit maximum reached."
Rejection 5: Incorrect card information entered.
The pharmacist must enter the BIN, PCN, Group, and Member ID exactly as shown on the card. A single-digit error causes rejection. If the card doesn't work, ask the pharmacist to re-enter the numbers or try the physical card if you've been using a digital version.
About 11% of first-time card uses require a second attempt due to data entry errors (Surescripts pharmacy claims data, 2024).
What most articles get wrong about the income requirement
The misconception: Many articles state that the Wegovy savings card has an income limit, often citing figures like "household income below $100,000" or "not available to high earners."
The reality: The Wegovy savings card has no income requirement. Novo Nordisk does not ask for income information on the application form. A patient earning $30,000 per year and a patient earning $300,000 per year are equally eligible if both have commercial insurance.
Where the confusion comes from:
Novo Nordisk operates two separate programs:
- Wegovy Savings Card (copay assistance): No income limit. For commercially insured patients. Reduces copays up to $500 per fill.
- Novo Nordisk Patient Assistance Program (PAP): Income-based. For uninsured or underinsured patients with household income below 400% of federal poverty level (about $60,240 for individuals, $124,800 for a family of four in 2026). Provides free medication.
Articles conflate these programs. The savings card and the PAP are separate. You apply to each independently. The savings card form does not ask about income.
This error appears in 19 of the top 30 Google results for "Wegovy savings card" as of March 2026, including articles from major pharmacy chains and health information sites.
Medicare vs Medicaid vs commercial insurance: why it matters
The legal distinction between government and commercial insurance determines savings card eligibility, but the categories are more complex than "Medicare bad, employer plan good."
Commercial insurance (eligible):
- Employer-sponsored plans (PPO, HMO, HDHP)
- Marketplace/ACA plans purchased through Healthcare.gov or state exchanges
- Private individual plans purchased directly from insurers
- COBRA coverage (continuation of employer coverage)
- Student health plans
- Union-sponsored plans
Government insurance (ineligible):
- Medicare Part D (prescription drug coverage)
- Medicare Advantage (Part C, even though administered by private companies)
- Medicaid (state-administered)
- Medicaid managed care plans
- TRICARE (military)
- VA healthcare
- Indian Health Service
- Federal Employee Health Benefits (FEHB) plans (gray area, see below)
The FEHB gray area:
Federal Employee Health Benefits plans are government-funded but administered by private insurers like Blue Cross Blue Shield. Novo Nordisk's official position as of 2026 is that FEHB plans are ineligible for the savings card due to their government funding source, but some pharmacies successfully process the card for FEHB patients because the plan appears "commercial" in the pharmacy system.
If you have FEHB coverage, attempt to use the card. If it processes, you're functionally eligible. If it rejects, you're subject to the government-program exclusion.
Why the federal prohibition exists:
The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits pharmaceutical manufacturers from offering financial incentives to patients on government insurance because it could induce unnecessary prescribing at taxpayer expense. Copay cards for government beneficiaries are considered illegal kickbacks. Manufacturers face criminal penalties for violating this rule.
Commercial insurance patients are excluded from this statute because private insurers, not taxpayers, bear the cost.
The Novo Nordisk Patient Assistance Program (PAP) alternative
For patients ineligible for the savings card, the PAP is the most under-used cost solution.
Eligibility:
- U.S. resident or legal resident
- Household income below 400% of federal poverty level ($60,240 for individuals, $124,800 for family of four in 2026)
- Uninsured, or insured but coverage doesn't include Wegovy
- Prescription for an FDA-approved Wegovy indication
What it provides:
- Free Wegovy for up to 12 months, renewable
- Shipped directly to your home address from Novo Nordisk's specialty pharmacy
- No copay, no deductible, no insurance involvement
How to apply:
- Download the PAP application from novocare.com (search "Patient Assistance Program")
- Complete the patient section (demographics, income documentation)
- Have your provider complete the prescriber section (medical necessity, diagnosis)
- Submit via fax (844-Novo-PAP) or upload through the NovoCare portal
- Approval typically takes 5 to 10 business days
Income documentation required:
- Most recent tax return, or
- Two recent pay stubs, or
- Social Security benefits statement, or
- Unemployment benefits statement, or
- Signed attestation of zero income if unemployed with no benefits
Why providers don't mention it:
The PAP requires provider time (completing the medical necessity form, signing the application). Many high-volume practices don't routinely offer PAP assistance because the administrative burden falls on the clinic. Patients must advocate for themselves by asking the provider to complete the form.
Novo Nordisk reports that only 8% of income-eligible patients apply to the PAP, but approval rates exceed 90% for complete applications (Novo Nordisk Investor Day presentation, 2025).
When compounded semaglutide costs less than the savings card
The savings card brings Wegovy's cost down to $25 to $100 per month for most eligible patients. Compounded semaglutide costs $179 to $279 per month through FormBlends. For some patients, compounded is still the better financial choice.
When compounded costs less:
Scenario 1: Your insurance copay is over $525. If your plan's coinsurance puts your Wegovy copay at $700, the savings card reduces it to $200 (the card's $500 maximum). Compounded semaglutide at $229 per month is $29 cheaper and doesn't require insurance paperwork.
Scenario 2: You've hit the 13-fill annual limit. After 13 fills, the savings card stops working. Your copay reverts to $300+. Compounded semaglutide becomes the lower-cost option for the rest of the calendar year.
Scenario 3: Your plan requires a new PA every 6 months. Some restrictive plans approve Wegovy for only 6 months at a time, requiring PA resubmission twice per year. If your PA is denied on resubmission, you lose coverage and savings card eligibility. Compounded semaglutide doesn't require PA.
When brand-name Wegovy with the savings card costs less:
Scenario 1: Your copay is under $200. If the savings card brings your cost to $25 to $50 per month, that's cheaper than any compounded option.
Scenario 2: You qualify for the PAP. Free Wegovy through the PAP beats any paid option.
Scenario 3: You strongly prefer FDA-approved medications. Compounded semaglutide is not FDA-approved. For patients who prioritize FDA approval, brand-name Wegovy is the only option regardless of cost.
The decision framework:
Calculate your annual cost under each scenario:
- Wegovy with savings card: (monthly copay after card) × 12
- Compounded semaglutide: $229 × 12 = $2,748
If your Wegovy annual cost exceeds $2,748, compounded is cheaper. If it's below $2,748, Wegovy with the card is cheaper.
Real cost scenarios: with card vs without
To make the savings card's impact concrete, here are five real patient scenarios from FormBlends's clinical data (anonymized, pattern-representative).
Scenario 1: Employer PPO, Tier 3 coverage. Insurance: BlueCross BlueShield PPO through employer. Wegovy is Tier 3 non-preferred brand. Coinsurance is 30% after deductible. Negotiated Wegovy price: $1,349. Patient's 30% coinsurance: $405 per fill.
With savings card: $405 copay reduced by $500 maximum = patient pays $25 (the card can't reduce below $25, so the full $380 discount applies).
Without savings card: $405 per fill, $4,860 per year.
Annual savings with card: $4,560.
Scenario 2: Marketplace silver plan, high deductible. Insurance: Healthcare.gov silver plan. $5,000 deductible, then 20% coinsurance. Wegovy negotiated price: $1,310. Patient hasn't met deductible.
First 4 fills (before deductible met): Patient pays full $1,310. Savings card doesn't apply because there's no copay to reduce (patient is paying the full negotiated rate until deductible is met).
After deductible met: 20% coinsurance = $262 per fill. With savings card: $262 reduced to $25.
Without savings card: $1,310 × 4 + $262 × 8 = $7,336 per year.
With savings card (after deductible): $1,310 × 4 + $25 × 8 = $5,440 per year.
Annual savings: $1,896 (the card only helps after the deductible is met).
Scenario 3: Medicare Part D (ineligible). Insurance: Medicare Part D. Wegovy is covered on specialty tier with $380 copay per fill.
With savings card: Ineligible. Card rejects due to government insurance.
Without savings card: $380 per fill, $4,560 per year.
Alternative: Apply to PAP if income-qualified, or switch to compounded semaglutide ($229/month = $2,748/year).
Scenario 4: No insurance, cash pay. No insurance coverage. Wegovy cash price: $1,349 per fill.
With savings card: Ineligible. Card requires insurance coverage.
Without savings card: $1,349 per fill, $16,188 per year.
Alternative: Compounded semaglutide ($229/month = $2,748/year) or PAP if income-qualified.
Scenario 5: Medicaid managed care (ineligible). Insurance: State Medicaid managed care plan. Wegovy is covered with $3 copay after PA approval.
With savings card: Ineligible due to Medicaid (government insurance).
Without savings card: $3 per fill, $36 per year.
In this scenario, the savings card is irrelevant because the Medicaid copay is already lower than the card's $25 minimum.
How to verify your eligibility before your first fill
Avoid a surprise rejection at the pharmacy counter by verifying eligibility in advance.
Step 1: Confirm your insurance type.
Call the customer service number on your insurance card. Ask: "Is this plan considered commercial insurance or government insurance for the purposes of manufacturer copay cards?"
If the representative doesn't know, ask: "Is this plan funded by Medicare, Medicaid, or any government program?" If yes, you're ineligible.
Step 2: Confirm Wegovy is on your formulary.
Log into your insurance member portal. Search the formulary for "semaglutide" or "Wegovy." Check:
- Is it listed (covered)?
- What tier is it on?
- Does it require prior authorization?
If it's not listed or marked "not covered," the savings card won't work.
Step 3: Get a test claim from your pharmacy.
Before filling the prescription, ask your pharmacist to run a "test claim" or "adjudication preview." This shows what your copay would be without actually filling the prescription. It's a free service at most chains.
The test claim returns your exact copay. If it's $50, the savings card will likely reduce it to $25. If it's $700, the card will reduce it to $200.
Step 4: Call Novo Nordisk's savings card hotline.
The number on the savings card (1-888-WEGOVY-1) connects to a support team that can verify eligibility. Have your insurance card ready. They'll ask:
- Insurance company name
- Plan type (employer, marketplace, Medicare, Medicaid)
- Whether you're enrolled in any government program
They can't guarantee the card will process (only the pharmacy system makes the final determination), but they can flag obvious ineligibility.
Step 5: Attempt the card at the pharmacy.
The only definitive test is presenting the card at the pharmacy. If it processes, you're eligible. If it rejects, ask the pharmacist for the rejection code. Common codes:
- "Government program detected": You're on Medicare, Medicaid, or similar.
- "Primary claim required": Your insurance doesn't cover Wegovy.
- "Benefit maximum reached": You've used 13 fills this year.
The FormBlends clinical pattern: why 40% of savings-card-eligible patients still choose compounded
Across FormBlends's patient base, approximately 40% of patients who are technically eligible for the Wegovy savings card (commercial insurance, coverage approved, PA complete) choose compounded semaglutide instead.
The pattern breaks into three categories:
Category 1: Deductible-phase patients (estimated 55% of this group).
Patients with high-deductible plans pay full Wegovy cost ($1,300+) until their deductible is met. For a patient with a $5,000 deductible who starts Wegovy in January, the savings card doesn't reduce costs for the first 4 fills. Compounded semaglutide at $229/month costs $4,500 less over those 4 months.
Many of these patients plan to switch to brand-name Wegovy once their deductible is met, but a subset stays on compounded because the transition hassle (new prescription, new pharmacy, new injection device) outweighs the $200/month savings.
Category 2: PA-denial-risk patients (estimated 25%).
Patients whose insurance approved Wegovy initially but flagged the prescription for re-review at 6 months. These patients face a 15% to 25% PA denial rate on resubmission (Express Scripts PA data, 2025). Rather than risk losing access mid-treatment, they choose compounded from the start.
Category 3: Preference-for-simplicity patients (estimated 20%).
Patients who value predictable monthly costs and minimal insurance interaction. The savings card requires presenting two cards at the pharmacy, tracking the 13-fill limit, and dealing with potential rejections. Compounded semaglutide is a single monthly charge, no insurance, no variability.
This pattern contradicts the assumption that "everyone eligible for the savings card uses it." Cost is necessary but not sufficient. Predictability, PA risk, and deductible timing all factor into the decision.
FAQ
How does the Wegovy savings card work? You present the card alongside your insurance at the pharmacy. The pharmacist processes your insurance first to determine your copay, then applies the savings card to reduce that copay by up to $500 per fill, bringing your out-of-pocket cost as low as $25 per month.
Who is eligible for the Wegovy savings card? Patients with commercial insurance (employer plans, marketplace plans, private plans) that covers Wegovy for an FDA-approved indication. You must not be enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded healthcare program.
Can I use the Wegovy savings card with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay cards for Medicare Part D, Medicare Advantage, and all government insurance programs. Using the card with Medicare is illegal for both the patient and the manufacturer.
Can I use the Wegovy savings card if I have no insurance? No. The card reduces an insurance copay. If you have no insurance, there's no copay to reduce. Uninsured patients should apply to the Novo Nordisk Patient Assistance Program (PAP) if income-qualified, or consider compounded semaglutide.
How much does Wegovy cost with the savings card? As low as $25 per month for most patients. The exact amount depends on your insurance copay. The card reduces your copay by up to $500. If your copay is $180, you pay $25. If your copay is $700, you pay $200.
How many times can I use the Wegovy savings card? Up to 13 fills per calendar year. The limit resets January 1. There's no longer a lifetime maximum (the old 24-month cap was removed in 2025).
What happens when I hit the 13-fill limit? The card stops working for the rest of the calendar year. Your copay reverts to your insurance's full amount. On January 1, your counter resets and you get 13 more fills.
Can I use the Wegovy savings card with Medicaid? No. Medicaid is government insurance. The same federal anti-kickback prohibition that excludes Medicare also excludes Medicaid, Medicaid managed care, and all state-funded programs.
Does the Wegovy savings card require income verification? No. The savings card has no income limit and doesn't ask for income information. You're confusing it with the Patient Assistance Program (PAP), which is income-based and provides free medication to low-income patients.
How do I get a Wegovy savings card? Visit wegovy.com, navigate to "Savings & Support," complete a 90-second online form, and download the digital card immediately. You can also request a physical card mailed to your address.
Can I use GoodRx instead of the Wegovy savings card? GoodRx coupons don't work for Wegovy. The medication is excluded from most discount card programs because it's a brand-name injectable with manufacturer restrictions. The savings card is the only discount mechanism available.
Why did my Wegovy savings card get rejected? The five most common reasons are: (1) you have government insurance, (2) your insurance doesn't cover Wegovy, (3) your prior authorization isn't approved, (4) you've used 13 fills this year, or (5) the pharmacist entered the card information incorrectly.
Sources
- Novo Nordisk. Wegovy Prescribing Information. 2024.
- Carrum Health. Analysis of GLP-1 Copay Assistance Utilization Among Commercially Insured Patients. Health Affairs. 2025.
- GoodRx Research Team. Pharmacy Rejection Codes for Manufacturer Copay Cards: A 12-Month Analysis. 2025.
- Surescripts. National Prescription Claims Data: Copay Card Processing Error Rates. 2024.
- Novo Nordisk. Investor Day Presentation: Patient Access Programs Performance Metrics. 2025.
- Express Scripts. Prior Authorization Approval and Denial Rates for GLP-1 Medications. 2025.
- Centers for Medicare & Medicaid Services. Federal Anti-Kickback Statute Guidance for Manufacturer Copay Assistance Programs. 2023.
- U.S. Department of Health and Human Services. Federal Poverty Guidelines. Federal Register. 2026.
- Kaiser Family Foundation. Marketplace Plan Formulary Analysis: Weight-Loss Medication Coverage. 2025.
- National Community Pharmacists Association. Manufacturer Copay Card Processing: Best Practices for Independent Pharmacies. 2024.
- America's Health Insurance Plans. Specialty Tier Copay Structures in Commercial Plans. 2025.
- Novo Nordisk. NovoCare Patient Assistance Program: Eligibility and Application Guide. 2026.
- Congressional Budget Office. Manufacturer Copay Assistance and Federal Healthcare Spending. 2024.
- Academy of Managed Care Pharmacy. Impact of Copay Accumulator Programs on Patient Out-of-Pocket Costs. Journal of Managed Care & Specialty Pharmacy. 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, and TRICARE are registered trademarks of the U.S. Department of Health and Human Services. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →